Advertisement

Topics

Jeffrey Adelglass, M.D., F.A.C.S. Company Profile

09:02 EDT 20th September 2017 | BioPortfolio


News Articles [88 Associated News Articles listed on BioPortfolio]

PAINWeek Attendees: It's Doctor vs Doctor—Jeffrey Fudin vs Jeffrey Gudin—at the 2017 National Conference

Montclair, NJ (PRWEB) August 08, 2017 PAINWeek®â€”the largest US pain conference for frontline practitioners—is celebra...

Jeffrey Tate

bmj;357/jun16_2/j2937/FAF1faCredit: Artists Management ZurichIn 1966 medical student Jeffrey Tate had a shock. Speaking about it later to the BBC, he said: “I failed my exams. I got entangled in a.....

CNN fires pro-Trump pundit Jeffrey Lord for 'Sieg Heil!' tweet

“Nazi salutes are indefensible,” a CNN spokesperson said. “Jeffrey Lord is no longer with the network.”

Amgen liefert durchwachsene Ergebnisse! - Aktienanalyse

Zürich - Amgen-Aktienanalyse des Analysten Jeffrey Hung von der UBS: Aktienanalyst Jeffrey Hung von der UBS bestätigt laut einer Aktienanalyse seine neutrale Haltung hinsichtlich den Aktien des Bio....

Amgen-Aktien: Quartalszahlen übertreffen Erwartungen! - Aktienanalyse

Zürich - Amgen-Aktienanalyse des Analysten Jeffrey Hung von der UBS: Aktienanalyst Jeffrey Hung von der UBS bestätigt laut einer Aktienanalyse seine neutrale Haltung hinsichtlich den Aktien des Bio....

Apple-Aktie: heiß ersehnter Superzyklus steht nun bevor! - Aktienanalyse

New York - Apple-Aktienanalyse von Analyst Jeffrey Kvaal von Instinet: Im Rahmen einer aktuellen Aktienanalyse bestätigt Analyst Jeffrey Kvaal vom Investmenthaus Instinet seine Kaufempfehlung für d....

Novartis-Aktie: Positive Geschäftsdynamik sollte sich fortsetzen - Kaufempfehlung - Aktienanalyse

London - Novartis-Aktienanalyse von Analyst Jeffrey Holford von Jefferies: Jeffrey Holford, Analyst von Jefferies, rät in einer aktuellen Aktienanalyse weiterhin zum Kauf der Aktie des Pharmakonzer.....

Sanofi-Aktie: Vielversprechender Marktstart des Asthmamittels Dupixent - Neues Kursziel - Aktienanalyse

London - Sanofi-Aktienanalyse von Analyst Jeffrey Holford von Jefferies: Jeffrey Holford, Analyst von Jefferies, senkt in einer aktuellen Branchenstudie das Kursziel für die Aktie des französischen....

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM

Julius Schachter, PhD, from the Department of Laboratory Medicine at UCSF, and Jeffrey Klausner, MD, from the Department of Public Health, are conducting a study to evaluate a type of test...

Regulation of Cerebral Blood Flow in Very Low Birth Weight Infants

Advances in newborn intensive care have lead to dramatic improvements in survival for the most premature infants—often weighing 1 pound at birth. Unfortunately, cerebral palsy, mental re...

Companies [26 Associated Companies listed on BioPortfolio]

Jeffrey Adelglass, M.D., F.A.C.S.

3v07 Medical Advertising

3v07 Medical Advertising is an intellectual and creative trust with extensive experience in all aspects of branding and advertising for medical devices, life sciences and pharmace...

Jeffrey Zindler

Dr. Jeffrey Fine

Jeffrey Modell Foundation

More Information about "Jeffrey Adelglass, M.D., F.A.C.S." on BioPortfolio

We have published hundreds of Jeffrey Adelglass, M.D., F.A.C.S. news stories on BioPortfolio along with dozens of Jeffrey Adelglass, M.D., F.A.C.S. Clinical Trials and PubMed Articles about Jeffrey Adelglass, M.D., F.A.C.S. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Jeffrey Adelglass, M.D., F.A.C.S. Companies in our database. You can also find out about relevant Jeffrey Adelglass, M.D., F.A.C.S. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record